



**ORIGINAL RESEARCH PAPER**

**General Medicine**

**A STUDY OF HBA1C IN NON DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROME:PROGNOSTIC SIGNIFICANCE**

**KEY WORDS:** Non Diabetic ;Acute Coronary Syndrome; Hba1c

<b>Dr.P.K.BAGHEL</b>	(MD) Professor ,Department of Medicine ,Shyam Shah Medical College and Sanjay Gandhi Memorial Hospital Rewa
<b>Dr.P.K.TAGORE</b>	(MD) Assisstant Professor ,,Department of Medicine ,Shyam Shah Medical College and Sanjay Gandhi Memorial Hospital Rewa
<b>Dr. ANUSRI UPENDRAN</b>	Department Of Medicine ,Shyam Shah medical College and Sanjay Gandhi Memorial Hospital Rewa.

<b>ABSTRACT</b>	<b>BACKGROUND:</b> Diabetes plays a major role in Coronary artery disease and complications. There is an exponential elevation of cardiovascular risk and complications with glucose status which also extends into the pre diabetic state.HbA1c levels can be independent predictor of cardiovascular risks.
	<b>AIM:</b> To assess the prognostic impact of HbA1c in non-diabetic with ACS.
	<b>MATERIALS and METHODS:</b> A cross sectional study was done on 172 non diabetics with ACS. HbA1c at admission was measured and relation to Major Adverse Cardiovascular Events in the form of arrhythmias, cardiogenic shock or cardiac failure was assessed.
	<b>OBSERVATIONS:</b> In our study 71.5% were males and 28.5% females. Out of 172 patients, 76 had HbA1c level above 5.7 % (high risk group), of which 55.6%(n=42) had cardio-vascular complications. In the rest of the 96 patients with HbA1c less than 5.75% (low risk group), it was 32.29% (n=31)
	<b>CONCLUSION:</b> This study demonstrated non-diabetics with ACS are associated with poorer outcomes when they have pre-diabetic levels of HbA1c. Hence baseline HbA1c should be considered in predicting the complications and prognosis of the disease.

**INTRODUCTION**

In 2000, there were an estimated 29.8 million people with CHD in India out of a total estimated population of 1.03 billion, nearly 3% overall prevalence, 3–4% in rural areas and 8–10% in urban areas in 2003<sup>14</sup>. In 2008, it increased to 6% ( rural) and 12% (urban) 5..Glucose intolerance is associated with a 1.5-fold increase in the risk of developing cardiovascular disease<sup>6</sup>. Of the Micro and macrovascular complications in diabetes, the later can develop even before the full blown disease manifests.<sup>7-8</sup>. Increased blood glucose is an independent risk factor along with platelet aggregation and activation leading to thrombus formation .9-10Elevated plasma fibrinogen, reduced fibrinolytic activity , reduced tissue plasminogen activator activity due to increased plasma concentration of and enhanced binding to its inhibitor, (plasminogen activator inhibitor) seen in association with hyperglycemic states<sup>11-13</sup>. Glycated proteins and advanced glycation end products accelerates the atherosclerosis by worsening endothelial dysfunction.<sup>14</sup>. There is a significant prevalence (40%) of impaired glucose metabolism in non-diabetic ACS on admission.<sup>15-16</sup>.There has been various studies with increased mortality independent of diabetic status<sup>17</sup>.HbA1c as an independent predictor of cardiovascular risk has been established from various studies<sup>10-13</sup>. HbA1c is a simple, reliable and a long term measure of glycemic status. Studies done on those ACS patients undergoing coronary revascularization was shown to have increased association with high HbA1c levels<sup>7,8,9,18,19</sup>. Very few studies have been done in context of exposing the role in cardiovascular prognosis.

**AIMS AND OBJECTIVES**

1. To study and assess the prognostic impact of admission HbA1c values in patients without diabetes mellitus who were admitted with ACS.
2. To study the prevalence of ACS in pre diabetics.

**MATERIAL AND METHODS**

**Type of study:** Cross sectional observational study.

**Duration of Study:** July 2016 to June 2017

**Place of Study:** SSMC and Sanjay Gandhi Memorial Hospital, Rewa.

**Sample Size:** 172 Non diabetic patients admitted to medicine

ICCU with ACS.

**INCLUSION CRITERIA**

1. Non diabetic presenting with acute coronary syndrome
2. Age group 35-85 years.

**EXCLUSION CRITERIA**

1. Diabetes mellitus
2. Chronic kidney disease
3. Hemoglobinopathies
4. Sepsis
5. HbA1c >6.5%
6. Anemia
7. Not giving consent for the study.


**RESULTS**

**Table 1: Base line characteristics of participants**

Variables	Frequency (n=172)	Percent
Male	123	71.5%
Female	49	28.5%
BMI>25	37	21.5%
BMI<25	135	78.5%
Hypertension		
Yes	39	22.7%
No	133	77.3%
Tobacco Use		
Yes	91	52.9%
No	81	47.1%
HbA1c		
<5.69%	96	55.8%
>5.7%	76	44.2%

71.5% were males (mean age=57.57) and 28.5% females (mean age= 62.24). 22.7% (n=39) hypertensive and 21.5% (n=37) had BMI >25 .Majority of them were tobacco smokers and tobacco chewers (52.9%).High normal HbA1c values are seen in 44.2%. 75.6% (n=130) had STEMI, 22.7% (n=39) had NSTEMI and 3% had unstable angina.

**Figure 1: ECG findings of study participants**



Maximum findings was of ST elevation (64.0%) followed by ST depression (16.3%) and least with AV block & VT (1.2%)

**Table 2: Comparison of Cardio – vascular complications with HbA1C**

HbA1C	Major adverse Cardiovascular events								Total
	No Complications	LVF	Arrhythmia	Death	Reinfarct	Valvular Heart Damage	LVF & Arrhythmia	Shock	
>5.7% and above	34 (44%)	21 (27.63%)	11 (14.47%)	1 (1.31%)	2 (2.63%)	4 (5.26%)	1 (1.31%)	2 (2.63%)	76
<5.69% and below	65 (67%)	24 (25%)	0	0	3 (3.12%)	2 (2%)	2 (2%)	0	96

High proportion of cardio vascular complications (55.26%) were found, when HbA1C >5.7% and lower (32.29%) when HbA1 <5.7%. (p<0.001). Majority of them was left ventricular failure (27.63%) followed by arrhythmias (14.47%) Death was found in 1.31% in the high HbA1c group.

**Table: 3 Association of ejection fraction with HbA1c**

Ejection Fraction	HbA1C Values	
	≤40%	≥41%
>5.7% (n=76)	39 (51.32%)	37 (48.6%)
<5.69% (n=96)	27 (28%)	69 (71.8%)

51.32% had an ejection fraction lower than 40% in HbA1C levels > 5.7 with significant association (p = 0.002)

**Table: 4 Comparison of Cardiovascular complications with Ejection Fraction**

Cardio-Vascular Complication	Ejection Fraction	
	≤40% (n=66)	≥41% (n=106)
Nil	20 (30%)	79 (74.5%)
LVF	32 (48%)	13 (12.26%)
Arrhythmia	5 (7.5%)	6 (5.66%)
Death	0	1 (0.9%)
Reinfarct	2 (3%)	3 (2.83%)
Valvular Damage	5 (7.5%)	1 (0.9%)
LVF and Arrhythmia	2 (3%)	1 (0.9%)
Shock	0	2 (1.88%)

High proportion of total cardiovascular complications (69.69%) found in participants with ejection fraction <40% with significant association (p<0.001)

**Table 5: Comparison of HbA1c values with 2D ECHO findings**

HbA1C	2 D aECHO		
	Normal	RWMA	RWMA and Valvular abnormality
>5.7% (n=76)	9 (11.8%)	53 (69.7%)	14 (18.4%)
<5.69% (n=96)	29 (30.2%)	64 (66.6%)	3 (3.125%)

68% had Regional Wall Motion Abnormality and 9.9% had RWMA with acute valvular abnormalities, with higher proportions when HbA1C > 5.7. (p=0.001)

**Table 6: Comparison of Diagnosis with HbA1c Values**

HbA1C	Diagnosis		
	STEMI	NSTEMI	Unstable Angina
>5.7% (n=76)	64 (84.2%)	9 (11.8%)	3 (3.94%)
<5.69% (n=96)	66 (68.7%)	30 (31.2%)	0

Frequency distribution of acute coronary syndrome in the 2 groups.

**DISCUSSION**

Several studies show progressive relation between glucose concentrations and cardiovascular risks which extends into the pre diabetic states<sup>20-21</sup>. Caiet al<sup>22</sup> (2014) showed a strong association of HbA1c with CAD severity, after adjusting other risk factors. In contrast, Ertem A G et al.<sup>23</sup> showed no significant relationship (p=0.299). Our study recorded a prevalence of pre diabetic ACS of 44%. Similar studies by Dubey et al<sup>24</sup> (2016) and Singh et al<sup>25</sup> (2017) showed 18.2% and 64% respectively.

Our endpoints, major adverse cardiovascular events (MACE) was found to have significant association with pre diabetics (p<0.001). Similar studies by Vinita Elizabeth Mani and John<sup>26</sup> (2011) and Singh et al<sup>25</sup> (2017) showed increased amount of arrhythmias when HbA1c > 5.7%.

Our study observed that the percentage of RWMA with or without valve damage and significantly depressed cardiac function (51.32%) in HbA1c > 5.7%. Razaq et al.<sup>27</sup> (2013) demonstrated a linear decrease in EF with rising HbA1c levels in unstable angina (P = 0.0043)

Iribarren C et al<sup>28</sup> (2001) showed that each 1% increase in HbA1c was associated with an 8% increased relative risk of heart failure.

We recorded a mortality rate of 1.31% in high risk group and none in low risk group. Granger et al.<sup>29</sup> (2003) reported in-hospital mortality of 4.6% for the whole ACS sample compared to a total mortality of 0.6% in our study.

According to Corpus RA et al<sup>30</sup> (2003), Timmer JR et al<sup>31</sup> (2006), although crude mortality was higher with elevated HbA1c following adjustment for many cardiovascular risk factors, HbA1c values failed to predict in-hospital mortality. Chowdhury TA et al<sup>32</sup> (1998), Rasoul S et al<sup>33</sup> (2007) and Cicek G et al<sup>34</sup> (2011) suggested that HbA1c level was also a predictor of both in-hospital and long-term mortality.

**CONCLUSION**

We observed that there was a high prevalence of acute coronary syndrome in non-diabetic individuals. The pre diabetic patients also experienced an increased number of adverse cardiovascular complications including arrhythmias, re infarction, left ventricular failure and death with significant LV systolic dysfunction compared to non diabetics. We conclude that high normal HbA1c values can distinctly predict MACE in non-diabetics with ACS during hospital stay. Hence admission HbA1c levels can be a valuable tool to foresee the prognosis of Non diabetics with ACS.

**REFERENCES**

1. Registrar General, I. (2006). Population projections for India and states 2001–26. Report of the technical group on population projections constituted by the national commission on population.
2. Gupta, R., Joshi, P., Mohan, V., Reddy, K. S., & Yusuf, S. (2008). Epidemiology and causation of coronary heart disease and stroke in India. *Heart*, 94(1), 16-26.
3. Gupta, R. (2004). Coronary heart disease in India: Absolute numbers and economic burden. *Rapid response to Ghaffar A, Reddy KS, Singhi M. Burden of non-communicable diseases in South Asia. BMJ*, 328, 807-10.
4. Gupta, R. (2004). Burden of coronary heart disease in India. *Indian heart journal*, 57(6), 632-638.
5. Enas, E. A., Singh, V., Munjal, Y. P., Gupta, R., Patel, K. C., Bhandari, S., ... & Shah, B. (2008). Recommendations of the second Indo-US health summit on prevention and control of cardiovascular disease among Asian Indians. *Indian heart journal*, 61(3), 265-274.
6. Wilson, P. W., McGEE, D. L., & Kannel, W. B. (1981). Obesity, very low density

- lipoproteins, and glucose intolerance over fourteen years: the Framingham Study. *American Journal of Epidemiology*, 114(5), 697-704.
- 7) American Diabetes Association. Standards of medical care indiabates-2010. *Diabetes Care* 2010;33 Suppl 1:S11-61
  8. Sato, K. K., Hayashi, T., Harita, N., Yoneda, T., Nakamura, Y., Endo, G., & Kambe, H. (2009). Combined measurement of fasting plasma glucose and A1c is effective for the prediction of type 2 diabetes. *Diabetes Care*, 32(4), 644-646.
  9. Edelman, D., Olsen, M. K., Dudley, T. K., Harris, A. C., & Oddone, E. Z. (2004). Utility of hemoglobin A1c in predicting diabetes risk. *Journal of general internal medicine*, 19(12), 1175-1180.
  10. Shechter, M., Merz, C. N. B., Paul-Labrador, M. J., & Kaul, S. (2000). Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. *Journal of the American College of Cardiology*, 35(2), 300-307.
  11. Cubbon, R. M., Wheatcroft, S. B., Grant, P. J., Gale, C. P., Barth, J. H., Sapsford, R. J., ... & Hall, A. S. (2007). Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. *European heart journal*, 28(5), 540-545.
  12. Norhammar, A., Tenerz, L., Nilsson, G., Hamsten, A., Efendic, S., Rydén, L., & Malmberg, K. (2002). Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. *The Lancet*, 359(9324), 2140-2144.
  13. Foo, K., Cooper, J., Deaner, A., Knight, C., Suliman, A., Ranjadayalan, K., & Timmis, A. D. (2003). A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. *Heart*, 89(5), 512-516.
  14. Bauters, C., Ennezat, P. V., Tricot, O., Lauwierier, B., Lallemand, R., Saadouni, H., ... & Le Tourneau, T. (2007). Stress hyperglycaemia is an independent predictor of left ventricular remodelling after first anterior myocardial infarction in non-diabetic patients. *European heart journal*, 28(5), 546-552.
  15. O'sullivan, C. J., Hynes, N., Mahendran, B., Andrews, E. J., Avalos, G., Tawfik, S., ... & Sultan, S. (2006). Haemoglobin A1c (HbA1C) in non-diabetic and diabetic vascular patients. Is HbA1C an independent risk factor and predictor of adverse outcome?. *European journal of vascular and endovascular surgery*, 32(2), 188-197.
  16. Hadjadj, S., Coisne, D., Mauco, G., Ragot, S., Duengler, F., Sosner, P., ... & Marechaud, R. (2004). Prognostic value of admission plasma glucose and HbA1c in acute myocardial infarction. *Diabetic medicine*, 21(4), 305-310.
  17. Rasoul, S., Ottervanger, J. P., Bilo, H. J., Timmer, J. R., van't Hof, A. W., Dambrink, J. H., ... & Zijlstra, F. (2007). Glucose dysregulation in nondiabetic patients with ST-elevation myocardial infarction: acute and chronic glucose dysregulation in STEMI. *Neth J Med*, 65(3), 95-100.
  18. Laakso, M. (1997). Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus: lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus. *Journal of diabetes and its complications*, 11(2), 137-141.
  19. Clarkson, P., Celermajer, D. S., Donald, A. E., Sampson, M., Sorensen, K. E., Adams, M., ... & Deanfield, J. E. (1996). Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. *Journal of the American College of Cardiology*, 28(3), 573-579.
  20. Park, S., Barrett-Connor, E., Wingard, D. L., Shan, J., & Edelstein, S. (1996). GHB is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes: the Rancho Bernardo Study. *Diabetes care*, 19(5), 450-456.
  21. Gerstein, H. C. (1997). Glucose: a continuous risk factor for cardiovascular disease. *Diabetic Medicine*, 14(S3).
  22. Cai, A., Li, G., Chen, J., Li, X., Wei, X., Li, L., & Zhou, Y. (2014). Glycated hemoglobin level is significantly associated with the severity of coronary artery disease in non-diabetic adults. *Lipids in health and disease*, 13(1), 181.
  23. Ertem, A. G., Bağbancı, H., Kılıç, H., Yeter, E., & Akdemir, R. (2013). Relationship between HbA1c levels and coronary artery severity in nondiabetic acute coronary syndrome patients. *Turk Kardiyol Dern Ars*, 41(5), 389-95.
  24. T. N. Dubey, Kaustubh Mundada, A Arya. Correlation of HbA1c with mortality and severity in acute coronary syndrome. *International Journal of Contemporary Medical Research*. 2016;3:2244-2247.
  25. Singh S, Bansal M, Rani K, Gupta V. Prognostic significance of glycosylated hemoglobin in nondiabetic patients in acute coronary syndrome. *Heart India*. 2016 Jan 1;4(1):17.
  26. Mani, V. E., John, M., & Calton, R. (2011). Impact of HbA1c on acute cardiac states. *JAPI*, 59(6), 1-3.
  27. Razzaq, M. K. A., Rasheed, J. I., & Mohammad, H. S. (2013). The value of admission glucose and glycosylated hemoglobin in patients with acute coronary syndrome. *The Iraqi Postgraduate Medical Journal*, 12(1).
  28. Iribarren, C., Karter, A. J., Go, A. S., Ferrara, A., Liu, J. Y., Sidney, S., & Selby, J. V. (2001). Glycemic control and heart failure among adult patients with diabetes. *Circulation*, 103(22), 2668-2673.
  29. Granger, C. B., Goldberg, R. J., Dabbous, O., Pieper, K. S., Eagle, K. A., Cannon, C. P., ... & Fox, K. A. (2003). Predictors of hospital mortality in the global registry of acute coronary events. *Archives of internal medicine*, 163(19), 2345-2353.
  30. Corpus, R. A., O'Neill, W. W., Dixon, S. R., Timmis, G. C., & Devlin, W. H. (2003). Relation of hemoglobin A1c to rate of major adverse cardiac events in nondiabetic patients undergoing percutaneous coronary revascularization. *The American journal of cardiology*, 92(11), 1282-1286.
  31. Timmer, J. R., Ottervanger, J. P., Bilo, H. J. G., Dambrink, J. H. E., Miedema, K., Hoorntje, J. C. A., & Zijlstra, F. (2006). Prognostic value of admission glucose and glycosylated haemoglobin levels in acute coronary syndromes. *Journal of the Association of Physicians*, 99(4), 237-243.
  32. Chowdhury, T. A., & Lasker, S. S. (1998). Elevated glycated haemoglobin in non-diabetic patients is associated with an increased mortality in myocardial infarction. *Postgraduate medical journal*, 74(874), 480-481.
  33. Rasoul, S., Ottervanger, J. P., Bilo, H. J., Timmer, J. R., van't Hof, A. W., Dambrink, J. H., ... & Zijlstra, F. (2007). Glucose dysregulation in nondiabetic patients with ST-elevation myocardial infarction: acute and chronic glucose dysregulation in STEMI. *Neth J Med*, 65(3), 95-100.
  34. Cicek, G., Uyarel, H., Ergelen, M., Ayhan, E., Abanonu, G. B., Eren, M., & Gibson, C. M. (2011). Hemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. *Coronary artery disease*, 22(3), 131-137.